The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Sunwen Chou

Division of Infectious Diseases

Oregon Health and Science University

Portland

Oregon

USA

[email]@ohsu.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA. 2003 - 2012
  • Division of Infectious Diseases, Oregon Health and Science University and Department of Veterans Affairs Medical Center, Portland, OR 97239, USA. 2011
  • VA Medical Center P3ID, 3710 SW U.S. Veterans Hospital Road, Portland, OR 97239, USA. 2008
  • Medical and Research Services, VA Medical Center, Portland, Oregon 97201, USA. 1998 - 2006
  • VA Medical Center, Portland, Oregon 97201, USA. 1999 - 2000

References

  1. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Chou, S., Marousek, G., Bowlin, T.L. Antimicrob. Agents Chemother. (2012) [Pubmed]
  2. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. Chou, S. J. Clin. Virol. (2011) [Pubmed]
  3. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Chou, S., Bowlin, T.L. Antimicrob. Agents Chemother. (2011) [Pubmed]
  4. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Chou, S. Antimicrob. Agents Chemother. (2010) [Pubmed]
  5. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Chou, S., Marousek, G., Boivin, G., Goyette, N., Farhan, M., Ives, J.A., Elston, R. Transplantation (2010) [Pubmed]
  6. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Chou, S. Antimicrob. Agents Chemother. (2009) [Pubmed]
  7. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Chou, S. Rev. Med. Virol. (2008) [Pubmed]
  8. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. Chou, S., Marousek, G., Li, S., Weinberg, A. J. Clin. Virol. (2008) [Pubmed]
  9. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. Chou, S., Marousek, G.I. J. Virol. (2008) [Pubmed]
  10. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Chou, S., Marousek, G.I., Van Wechel, L.C., Li, S., Weinberg, A. Antimicrob. Agents Chemother. (2007) [Pubmed]
  11. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. Chou, S., Wechel, L.C., Marousek, G.I. J. Infect. Dis. (2007) [Pubmed]
  12. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Chou, S., Van Wechel, L.C., Marousek, G.I. Antimicrob. Agents Chemother. (2006) [Pubmed]
  13. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Chou, S., Marousek, G.I. Antimicrob. Agents Chemother. (2006) [Pubmed]
  14. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Chou, S., Van Wechel, L.C., Lichy, H.M., Marousek, G.I. Antimicrob. Agents Chemother. (2005) [Pubmed]
  15. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. Chou, S., Marousek, G.I., Senters, A.E., Davis, M.G., Biron, K.K. J. Virol. (2004) [Pubmed]
  16. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. Chou, S., Lurain, N.S., Thompson, K.D., Miner, R.C., Drew, W.L. J. Infect. Dis. (2003) [Pubmed]
  17. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. Chou, S., Waldemer, R.H., Senters, A.E., Michels, K.S., Kemble, G.W., Miner, R.C., Drew, W.L. J. Infect. Dis. (2002) [Pubmed]
  18. Cytomegalovirus drug resistance and clinical implications. Chou, S.W. Transpl. Infect. Dis (2001) [Pubmed]
  19. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Chou, S., Meichsner, C.L. Antimicrob. Agents Chemother. (2000) [Pubmed]
  20. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. Chou, S., Miner, R.C., Drew, W.L. J. Infect. Dis. (2000) [Pubmed]
  21. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. Chou, S., Lurain, N.S., Weinberg, A., Cai, G.Y., Sharma, P.L., Crumpacker, C.S. Antimicrob. Agents Chemother. (1999) [Pubmed]
  22. Antiviral drug resistance in human cytomegalovirus. Chou, S. Transpl. Infect. Dis (1999) [Pubmed]
  23. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. Chou, S., Marousek, G., Parenti, D.M., Gordon, S.M., LaVoy, A.G., Ross, J.G., Miner, R.C., Drew, W.L. J. Infect. Dis. (1998) [Pubmed]
 
WikiGenes - Universities